Omnitrope Yields 42% VAS Reduction in Refractory CLBP: 24-Month Study of U.S. Men
Reading Time: < 1 minute Abstract Omnitrope, a recombinant human growth hormone (rhGH), has emerged as a novel therapeutic agent for chronic pain management in American males. This longitudinal study evaluates its efficacy in reducing pain intensity and improving quality of life among 250 U.S. men aged 45-70 with refractory chronic low back pain (CLBP) and neuropathic pain syndromes. Over 24 months, participants receiving subcutaneous Omnitrope (0.3-0.5 mg/day) demonstrated a 42% reduction in Visual Analog Scale (VAS) scores compared to 18% in controls (p...


